PT3164117T - Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos - Google Patents

Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos

Info

Publication number
PT3164117T
PT3164117T PT158154971T PT15815497T PT3164117T PT 3164117 T PT3164117 T PT 3164117T PT 158154971 T PT158154971 T PT 158154971T PT 15815497 T PT15815497 T PT 15815497T PT 3164117 T PT3164117 T PT 3164117T
Authority
PT
Portugal
Prior art keywords
immediate release
release formulations
abuse deterrent
deterrent immediate
cellulose polysaccharides
Prior art date
Application number
PT158154971T
Other languages
English (en)
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Publication of PT3164117T publication Critical patent/PT3164117T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PT158154971T 2014-07-03 2015-07-01 Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos PT3164117T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462020726P 2014-07-03 2014-07-03

Publications (1)

Publication Number Publication Date
PT3164117T true PT3164117T (pt) 2023-12-12

Family

ID=55016221

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158154971T PT3164117T (pt) 2014-07-03 2015-07-01 Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos

Country Status (12)

Country Link
US (3) US11617712B2 (pt)
EP (1) EP3164117B1 (pt)
JP (1) JP6850131B2 (pt)
AU (1) AU2015284078B2 (pt)
BR (1) BR112016030648B1 (pt)
CA (1) CA2953396C (pt)
DK (1) DK3164117T3 (pt)
ES (1) ES2963078T3 (pt)
MX (1) MX2017000041A (pt)
PL (1) PL3164117T3 (pt)
PT (1) PT3164117T (pt)
WO (1) WO2016004170A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014024382B1 (pt) 2012-04-18 2022-08-09 SpecGx LLC Composições farmacêuticas de contenção de abuso de liberação imediata e seu processo de preparação
AU2015284078B2 (en) 2014-07-03 2020-01-30 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US11065246B2 (en) 2016-02-08 2021-07-20 SpecGx LLC Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
US11478426B2 (en) 2018-09-25 2022-10-25 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
CN110101679A (zh) * 2019-05-15 2019-08-09 上海宣泰生物科技有限公司 海藻小苏打微泡腾片及其制备方法和应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2211485A (en) 1940-08-13 Effervescent acetyl salicylic acid
JPS537495B2 (pt) 1973-05-21 1978-03-18
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4678661A (en) 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
JPH0747532B2 (ja) 1985-10-16 1995-05-24 花王株式会社 錠剤の製造方法
US5096714A (en) 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
WO1994015643A1 (en) 1992-12-30 1994-07-21 Fmc Corporation Readily available konjac glucomannan sustained release excipient
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US6071539A (en) 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
CA2343148C (en) 1998-09-10 2005-11-15 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances
US20080102121A1 (en) 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
FR2785191B1 (fr) 1998-11-02 2002-05-31 Rhodia Chimie Sa Utilisation de gommes xanthanes pour la preparation de compositions pharmaceutiques
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6340471B1 (en) 1999-12-30 2002-01-22 Alvin Kershman Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6660302B1 (en) 2000-09-06 2003-12-09 Chr. Hansen, Inc. Dry-powder film coating composition and method of preparation
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20080050422A1 (en) 2001-10-12 2008-02-28 Monosolrx, Llc. Method of administering a film product containing a drug
WO2003032954A1 (en) 2001-10-17 2003-04-24 Dr. Reddy's Laboratories Ltd. Stabilized pharmaceutical formulations containing amlodipine maleate
AUPR839001A0 (en) * 2001-10-19 2001-11-15 Eli Lilly And Company Dosage form, device and methods of treatment
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040005359A1 (en) 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
PL1842533T3 (pl) 2003-08-06 2013-08-30 Gruenenthal Gmbh Postać aplikacyjna zabezpieczona przed nadużyciem
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US7658944B2 (en) 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
AU2013206525B2 (en) 2003-11-26 2015-09-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006002836A1 (de) 2004-07-01 2006-01-12 Losan Pharma Gmbh Brausezusammensetzungen von einschlafmitteln
US8093408B2 (en) 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
EP2018160B1 (en) 2006-03-16 2011-12-14 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
AU2007230730B2 (en) 2006-03-24 2013-03-28 Auxilium International Holdings, Inc. Stabilized compositions containing alkaline labile drugs
JP5226661B2 (ja) 2006-04-06 2013-07-03 ターロ ファーマシューティカルズ ノース アメリカ インコーポレイテッド 親水コロイド重合体を含む新規な耐流出性製剤
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
ES2300188B1 (es) 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
KR101521989B1 (ko) 2007-03-02 2015-05-28 테이카 세이야쿠 가부시키가이샤 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제
EP2146690B1 (en) 2007-04-13 2018-03-21 Teva Pharmaceuticals International GmbH Oral cephalotaxine dosage forms
JP5177447B2 (ja) 2007-06-07 2013-04-03 佐藤製薬株式会社 速溶性及び可撓性を有するフィルム製剤
US20090124650A1 (en) 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
BRPI0815387B8 (pt) 2007-08-13 2021-05-25 Abuse Deterrent Pharmaceutical Llc composição farmacêutica, método para fazer uma composição farmacêutica e uso da composição farmacêutica
CA2700426C (en) 2007-09-25 2017-10-31 Galia Temtsin Krayz Compositions comprising lipophilic active compounds and method for their preparation
MX2010006694A (es) 2007-12-17 2010-09-07 Labopharm Inc Formulacion de liberacion controlada, preventiva de mal uso.
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
US7918929B2 (en) 2008-02-19 2011-04-05 John Christopher Sunnucks Water erodible denture adhesive
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
CN102089277B (zh) 2008-05-07 2014-02-12 大日本住友制药株式会社 环状胺-1-甲酸酯衍生物及含有其的药物组合物
KR20110053956A (ko) 2008-08-07 2011-05-24 아반토르 퍼포먼스 머티리얼스, 인크. 검 및 당 알콜을 포함하는 지속 방출 제제
CA2737257C (en) 2008-09-18 2016-11-15 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(.epsilon.-caprolactone)
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
WO2010089132A1 (en) * 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
DK2393487T3 (en) * 2009-02-06 2017-01-23 Egalet Ltd Pharmaceutical compositions resistant to abuse
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
EP2488029B1 (en) 2009-09-30 2016-03-23 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
JP5017516B2 (ja) 2009-11-13 2012-09-05 株式会社ホットアルバム炭酸泉タブレット 錠剤の製造方法
WO2011066980A2 (en) 2009-12-04 2011-06-09 Lars Holger Hermann Oral dosage forms with reduced potential for drug abuse
WO2011079074A1 (en) 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US20120321674A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for Preventing Abuse of Solid Dosage Forms
EP2538928B1 (en) 2010-02-24 2017-05-03 Cima Labs Inc. Abuse-resistant formulations
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
CA2798701A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcohol-resistant extended release dosage forms comprising venlafaxine
MX2012013021A (es) 2010-05-11 2012-12-17 Cima Labs Inc Formulaciones resistentes a alcohol.
EP2409683A1 (en) 2010-07-06 2012-01-25 KRKA, D.D., Novo Mesto Stable aqueous formulations comprising poorly water soluble active ingredients
AU2012219322A1 (en) 2011-02-17 2013-05-09 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
CA2853764C (en) 2011-11-22 2017-05-16 Watson Pharmaceuticals, Inc. Immediate release abuse deterrent tablet
EP2838536B1 (en) * 2012-04-18 2017-08-09 Mallinckrodt LLC Immediate release pharmaceutical compositions with abuse deterrent properties
BR112014024382B1 (pt) 2012-04-18 2022-08-09 SpecGx LLC Composições farmacêuticas de contenção de abuso de liberação imediata e seu processo de preparação
EP2877161A1 (en) 2012-07-06 2015-06-03 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
CA2791206A1 (en) * 2012-09-28 2014-03-28 Pharmascience Inc. Abuse deterrent pharmaceutical formulation
MX363844B (es) 2013-03-15 2019-04-05 SpecGx LLC Forma de dosificación sólida de disuasivo del abuso para liberación inmediata con marca funcional.
AU2015284078B2 (en) 2014-07-03 2020-01-30 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides

Also Published As

Publication number Publication date
EP3164117B1 (en) 2023-09-06
US11517521B2 (en) 2022-12-06
MX2017000041A (es) 2017-05-01
US20160000703A1 (en) 2016-01-07
US11583493B2 (en) 2023-02-21
CA2953396A1 (en) 2016-01-07
ES2963078T3 (es) 2024-03-25
BR112016030648A2 (pt) 2021-09-08
US11617712B2 (en) 2023-04-04
WO2016004170A1 (en) 2016-01-07
PL3164117T3 (pl) 2024-03-11
BR112016030648B1 (pt) 2023-10-03
DK3164117T3 (da) 2023-12-04
EP3164117A4 (en) 2017-12-06
AU2015284078B2 (en) 2020-01-30
AU2015284078A1 (en) 2017-01-05
JP6850131B2 (ja) 2021-03-31
EP3164117A1 (en) 2017-05-10
CA2953396C (en) 2022-11-08
JP2017519783A (ja) 2017-07-20
US20200368148A1 (en) 2020-11-26
US20180296467A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
PL3053430T3 (pl) Prasa belująca
GB201413021D0 (en) Beyond 2
ZA201608046B (en) Pesticidal compositions and related methods
PT3164117T (pt) Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos
AU357569S (en) Chopping boards
PT3143852T (pt) Equipamento de motocultura
PL3262921T3 (pl) Prasa
EP3221147C0 (de) Nicht brennbarer schichtstoff
AU361518S (en) Chopping board
HK1248993A1 (zh) 幻覺單粒鑲
PL3157321T3 (pl) Rolnicza prasa do belowania
GB201800538D0 (en) Games
HK1215212A1 (zh) 遊戲裝置
GB2546148B (en) Animal deterrent
GB201519042D0 (en) Sleeved tetherball games
ZA201509077B (en) Safety net
GB201509274D0 (en) Improvements in agricultural equipment
GB201704057D0 (en) Improvements in agricultural equipment
GB201703217D0 (en) Catch
GB201415801D0 (en) Cat Fight Deterrent Colar
ZA201500415B (en) Apertured safety net
GB201406124D0 (en) Catch it 2
GB201409009D0 (en) Chopping board
GB201403949D0 (en) Play Made 1
IL231634A0 (en) Sensory simulation in home video games